Financhill
Sell
50

PRAX Quote, Financials, Valuation and Earnings

Last price:
$43.54
Seasonality move :
45.53%
Day range:
$43.66 - $45.80
52-week range:
$26.70 - $91.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
101.98x
P/B ratio:
2.05x
Volume:
178K
Avg. volume:
330.2K
1-year change:
10.61%
Market cap:
$902.3M
Revenue:
$8.6M
EPS (TTM):
-$10.72

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRAX
Praxis Precision Medicines
$183.1K -$3.21 -44.31% -90.29% $97.67
CVM
CEL-SCI
-- -- -- -- $8.00
IGC
IGC Pharma
$305K -$0.02 3.39% -50% $3.88
LCTX
Lineage Cell Therapeutics
$1.7M -$0.03 4.59% -- $3.92
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$21.6M -- 0.09% -- $14.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRAX
Praxis Precision Medicines
$44.30 $97.67 $902.3M -- $0.00 0% 101.98x
CVM
CEL-SCI
$2.25 $8.00 $6.8M -- $0.00 0% --
IGC
IGC Pharma
$0.30 $3.88 $23.9M -- $0.00 0% 17.64x
LCTX
Lineage Cell Therapeutics
$0.81 $3.92 $185.1M -- $0.00 0% 17.89x
NBY
NovaBay Pharmaceuticals
$0.60 $0.85 $3.5M -- $0.00 0% 0.16x
PLX
Protalix BioTherapeutics
$1.49 $14.00 $118.6M 37.25x $0.00 0% 2.09x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRAX
Praxis Precision Medicines
-- 1.175 -- 10.45x
CVM
CEL-SCI
-- -1.324 -- --
IGC
IGC Pharma
2.1% 0.230 0.51% 0.21x
LCTX
Lineage Cell Therapeutics
-- 1.726 -- 3.68x
NBY
NovaBay Pharmaceuticals
4.54% -0.941 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- -1.054 -- 1.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRAX
Praxis Precision Medicines
-- -$74.7M -59.11% -59.11% -856.97% -$53M
CVM
CEL-SCI
-- -$6.4M -- -- -- -$4.4M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
LCTX
Lineage Cell Therapeutics
$1.5M -$6.5M -22.68% -22.68% -433.09% -$5M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M

Praxis Precision Medicines vs. Competitors

  • Which has Higher Returns PRAX or CVM?

    CEL-SCI has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of --. Praxis Precision Medicines's return on equity of -59.11% beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$3.29 $445.5M
    CVM
    CEL-SCI
    -- -$2.40 --
  • What do Analysts Say About PRAX or CVM?

    Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 10567.73%. Given that CEL-SCI has higher upside potential than Praxis Precision Medicines, analysts believe CEL-SCI is more attractive than Praxis Precision Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    8 0 1
    CVM
    CEL-SCI
    1 0 0
  • Is PRAX or CVM More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.271, suggesting its less volatile than the S&P 500 by 72.891%.

  • Which is a Better Dividend Stock PRAX or CVM?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or CVM?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than CEL-SCI quarterly revenues of --. Praxis Precision Medicines's net income of -$69.3M is lower than CEL-SCI's net income of -$6.6M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    101.98x -- $7.5M -$69.3M
    CVM
    CEL-SCI
    -- -- -- -$6.6M
  • Which has Higher Returns PRAX or IGC?

    IGC Pharma has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -711.67%. Praxis Precision Medicines's return on equity of -59.11% beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$3.29 $445.5M
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About PRAX or IGC?

    Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma has higher upside potential than Praxis Precision Medicines, analysts believe IGC Pharma is more attractive than Praxis Precision Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    8 0 1
    IGC
    IGC Pharma
    2 0 0
  • Is PRAX or IGC More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.852%.

  • Which is a Better Dividend Stock PRAX or IGC?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or IGC?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than IGC Pharma quarterly revenues of $257K. Praxis Precision Medicines's net income of -$69.3M is lower than IGC Pharma's net income of -$1.8M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 17.64x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    101.98x -- $7.5M -$69.3M
    IGC
    IGC Pharma
    17.64x -- $257K -$1.8M
  • Which has Higher Returns PRAX or LCTX?

    Lineage Cell Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -275.57%. Praxis Precision Medicines's return on equity of -59.11% beat Lineage Cell Therapeutics's return on equity of -22.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$3.29 $445.5M
    LCTX
    Lineage Cell Therapeutics
    97.6% -$0.02 $77.7M
  • What do Analysts Say About PRAX or LCTX?

    Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 383.24%. Given that Lineage Cell Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Lineage Cell Therapeutics is more attractive than Praxis Precision Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    8 0 1
    LCTX
    Lineage Cell Therapeutics
    4 1 0
  • Is PRAX or LCTX More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.517, suggesting its more volatile than the S&P 500 by 51.713%.

  • Which is a Better Dividend Stock PRAX or LCTX?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or LCTX?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than Lineage Cell Therapeutics quarterly revenues of $1.5M. Praxis Precision Medicines's net income of -$69.3M is lower than Lineage Cell Therapeutics's net income of -$4.1M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 17.89x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    101.98x -- $7.5M -$69.3M
    LCTX
    Lineage Cell Therapeutics
    17.89x -- $1.5M -$4.1M
  • Which has Higher Returns PRAX or NBY?

    NovaBay Pharmaceuticals has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -49.65%. Praxis Precision Medicines's return on equity of -59.11% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$3.29 $445.5M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About PRAX or NBY?

    Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Praxis Precision Medicines has higher upside potential than NovaBay Pharmaceuticals, analysts believe Praxis Precision Medicines is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    8 0 1
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is PRAX or NBY More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

  • Which is a Better Dividend Stock PRAX or NBY?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or NBY?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Praxis Precision Medicines's net income of -$69.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    101.98x -- $7.5M -$69.3M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns PRAX or PLX?

    Protalix BioTherapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -35.79%. Praxis Precision Medicines's return on equity of -59.11% beat Protalix BioTherapeutics's return on equity of 10.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRAX
    Praxis Precision Medicines
    -- -$3.29 $445.5M
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
  • What do Analysts Say About PRAX or PLX?

    Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 839.6%. Given that Protalix BioTherapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Protalix BioTherapeutics is more attractive than Praxis Precision Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRAX
    Praxis Precision Medicines
    8 0 1
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is PRAX or PLX More Risky?

    Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.210, suggesting its less volatile than the S&P 500 by 120.951%.

  • Which is a Better Dividend Stock PRAX or PLX?

    Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRAX or PLX?

    Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Praxis Precision Medicines's net income of -$69.3M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 37.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 2.09x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRAX
    Praxis Precision Medicines
    101.98x -- $7.5M -$69.3M
    PLX
    Protalix BioTherapeutics
    2.09x 37.25x $10.1M -$3.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Is TTD The Big Winner If Pharma Ads Are Banned?
Is TTD The Big Winner If Pharma Ads Are Banned?

Last week, Senators Bernie Sanders and Angus King introduced a…

Is Palantir Stock Overvalued?
Is Palantir Stock Overvalued?

By every traditional yardstick, including a price‑to‑sales well above 100,…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 16

VEON [VEON] is up 3.1% over the past day.

Buy
74
DAVE alert for Jun 16

Dave [DAVE] is up 3.51% over the past day.

Buy
54
DAR alert for Jun 16

Darling Ingredients [DAR] is up 7.55% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock